Trial · NCT03176693
Preoperative Alpha Blockade for Pheochromocytoma
NCT03176693, Phase 3, Completed, University of California, Los Angeles; results first posted 2023-11-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Preoperative Alpha Blockade for Pheochromocytoma. Trials, record NCT03176693. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03176693
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Preoperative Alpha Blockade for Pheochromocytoma
- NCT number
- NCT03176693
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 39 participants, actual
- Lead sponsor
- University of California, Los Angeles
- Conditions
- Pheochromocytoma, Paraganglioma
- Interventions
- Phenoxybenzamine, Doxazosin
- First posted
- 2017-06-05
- Last updated
- 2023-11-20
- Results first posted
- 2023-11-20
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hemodynamic Instability | Intraoperative, approximately 90 minutes | Proportion of operative time outside target thresholds: SBP \>180 or \<80; DBP \> 90; MAP\>150 or \<50; HR\>90. Arterial line blood pressure measurements were extracted from the electronic medical record every 60 seconds. |
| Secondary | Mortality | 30 days postoperatively | Death within 30 days of surgery |
| Secondary | Daily Cost of Drug | Preoperative (2-3 weeks prior to surgery) | |
| Secondary | Quality of Life- Physical Functioning, Role Limitations Due to Physical Problems, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role-limitations Due to Emotional Problems, and Mental Health | From date of surgery (-2 to 3 weeks, -1 day, 30 days, 3 months, 6 months, 1 year) | Patients will take the SF-36 as well as a symptom survey describing the frequency and impact on their quality of life at several time points including prior to starting alpha blockade, immediately prior to surgery after being sufficiently blocked, and postoperatively at 30 days, 3 months, 6 months, and 1 year |
| Secondary | Morbidity as Assessed by Occurrence of Adverse Events | Postoperatively during inpatient stay and during readmissions up to 30 days postoperatively | Morbidity will be graded by Clavien Classification of adverse events |
| Secondary | Participants Admitted to Post-operative Intensive Care Unit (ICU) | up to 30 days post-surgery |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Hemodynamic Instability | Intraoperative, approximately 90 minutes | percentage of total operative time | MEDIAN | |
| SECONDARY | Mortality | 30 days postoperatively | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Daily Cost of Drug | Preoperative (2-3 weeks prior to surgery) | Dollars | MEDIAN | |
| SECONDARY | Quality of Life- Physical Functioning, Role Limitations Due to Physical Problems, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role-limitations Due to Emotional Problems, and Mental Health | From date of surgery (-2 to 3 weeks, -1 day, 30 days, 3 months, 6 months, 1 year) | Due to staff turnover and COVID-19 restrictions, data was not collected or analyzed. | ||
| SECONDARY | Morbidity as Assessed by Occurrence of Adverse Events | Postoperatively during inpatient stay and during readmissions up to 30 days postoperatively | events | NUMBER | |
| SECONDARY | Participants Admitted to Post-operative Intensive Care Unit (ICU) | up to 30 days post-surgery | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Hemodynamic Instability | Phenoxybenzamine | 14 | Inter-Quartile Range 5 to 34 | percentage of total operative time | |
| Hemodynamic Instability | Doxazosin | 13 | Inter-Quartile Range 3 to 33 | percentage of total operative time | |
| Mortality | Phenoxybenzamine | 0 | Participants | ||
| Mortality | Doxazosin | 0 | Participants | ||
| Daily Cost of Drug | Phenoxybenzamine | 442.20 | Inter-Quartile Range 323.44 to 634.58 | Dollars | |
| Daily Cost of Drug | Doxazosin | 5.06 | Inter-Quartile Range 1.88 to 8.92 | Dollars | |
| Morbidity as Assessed by Occurrence of Adverse Events | Phenoxybenzamine | 0 | events | ||
| Morbidity as Assessed by Occurrence of Adverse Events | Doxazosin | 0 | events | ||
| Participants Admitted to Post-operative Intensive Care Unit (ICU) | Phenoxybenzamine | 2 | Participants | ||
| Participants Admitted to Post-operative Intensive Care Unit (ICU) | Doxazosin | 1 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phenoxybenzamine | 19 | |
| Overall Study | STARTED | Doxazosin | 20 | |
| Overall Study | COMPLETED | Phenoxybenzamine | 19 | |
| Overall Study | COMPLETED | Doxazosin | 20 | |
| Overall Study | NOT COMPLETED | Phenoxybenzamine | 0 | |
| Overall Study | NOT COMPLETED | Doxazosin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Phenoxybenzamine | 0 | 19 |
| Total, all-cause mortality | Doxazosin | 0 | 20 |
| Total, other adverse events | Phenoxybenzamine | 0 | 19 |
| Total, other adverse events | Doxazosin | 0 | 20 |
| Total, serious adverse events | Phenoxybenzamine | 0 | 19 |
| Total, serious adverse events | Doxazosin | 0 | 20 |
Source ClinicalTrials.gov
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Phenoxybenzamine vs Doxazosin: Mortality | Trial comparisons |
| Phenoxybenzamine vs Doxazosin: Participants Admitted to Post-operative Intensive Care Unit (ICU) | Trial comparisons |
| Phenoxybenzamine vs Doxazosin: deaths from any cause | Trial comparisons |
| Phenoxybenzamine vs Doxazosin: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03176693
GET https://conductscience.org/api/trials/v1/NCT03176693/registered